For the past 100 years, we’ve been flying blind with regard to Alzheimer’s and Parkinson’s. Despite spending over US$100 billion dollars in the past three decades in clinical trials and drug development in the US alone, there is no treatment in sight for Alzheimer’s and Parkinson’s. Find out why effective drug development has been so challenging for pharmaceutical companies. Discover how Amprion’s breakthrough Prion Early Detection Science is poised to change the game in drug development. Our technology enables pharmaceutical companies to develop drugs targeting the molecular defects of the disease. We believe by tracking the bad actors at the most fundamental level — the molecular level with prions / misfolded proteins — this will bring the most significant impact in developing drugs for personalized biomarker profiles. We believe prion tracking is the revolutionary pathway in finding effective treatments for Alzheimer’s and Parkinson’s. We are working hard to accelerate successful drug development for Alzheimer’s and Parkinson’s.